Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bev-ICG NIR-II Endoscopy for GI Lesions
NCT06430372Phase 1Recruiting
- Sponsor
- Institute of Automation, Chinese Academy of Sciences
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Bev-ICG in gastrointestinal carcinoma, dysplasia and gastrointestinal polyp, sponsored by Institute of Automation, Chinese Academy of Sciences. Primary endpoint: Validation of NIR-II endoscope and probe targeting VEGF-A. Started Jul 2023; status: recruiting.
02
Drugs
Bev-ICG
03
Conditions
gastrointestinal carcinomadysplasiagastrointestinal polyp
Beyond the preview
Go deeper on NCT06430372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430372.